AtriCure (NASDAQ:ATRC) Stock Rating Upgraded by UBS Group

AtriCure (NASDAQ:ATRC) was upgraded by research analysts at UBS Group to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

ATRC has been the subject of a number of other research reports. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Finally, Canaccord Genuity Group increased their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $48.50.

AtriCure Stock Performance

NASDAQ:ATRC opened at $40.89 on Tuesday. The stock has a 50 day simple moving average of $30.68 and a 200 day simple moving average of $31.30. The stock has a market cap of $2.08 billion, a P/E ratio of 194.72 and a beta of 1.24. AtriCure has a 1-year low of $25.36 and a 1-year high of $43.18. The company has a current ratio of 4.22, a quick ratio of 3.18 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts anticipate that AtriCure will post 0.2 earnings per share for the current year.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total value of $85,950.00. Following the sale, the director owned 26,373 shares of the company’s stock, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.00% of the stock is owned by insiders.

Institutional Trading of AtriCure

Several institutional investors and hedge funds have recently modified their holdings of ATRC. Smartleaf Asset Management LLC boosted its stake in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares in the last quarter. Scotia Capital Inc. grew its position in AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after acquiring an additional 457 shares during the last quarter. ProShare Advisors LLC grew its position in AtriCure by 6.6% in the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after acquiring an additional 543 shares during the last quarter. Captrust Financial Advisors raised its stake in AtriCure by 7.9% during the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after acquiring an additional 579 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in AtriCure by 5.3% during the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after purchasing an additional 683 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.